Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 15 04:00PM ET
1.83
Dollar change
-0.25
Percentage change
-12.26
%
Index- P/E0.06 EPS (ttm)30.60 Insider Own0.18% Shs Outstand0.40M Perf Week-29.81%
Market Cap0.73M Forward P/E- EPS next Y-18.88 Insider Trans-98.26% Shs Float0.40M Perf Month-22.67%
Income-0.12M PEG- EPS next Q-5.38 Inst Own7.86% Short Float8.20% Perf Quarter-87.17%
Sales0.00M P/S- EPS this Y-3731.13% Inst Trans-76.10% Short Ratio0.08 Perf Half Y-91.23%
Book/sh25.13 P/B0.07 EPS next Y7.04% ROA-1.36% Short Interest0.03M Perf Year-94.04%
Cash/sh29.97 P/C0.06 EPS next 5Y- ROE-3.12% 52W Range2.05 - 49.80 Perf YTD-87.85%
Dividend Est.- P/FCF- EPS past 5Y- ROI-1.81% 52W High-96.34% Beta0.16
Dividend TTM- Quick Ratio2.17 Sales past 5Y0.00% Gross Margin- 52W Low-10.98% ATR (14)0.35
Dividend Ex-Date- Current Ratio2.17 EPS Y/Y TTM107.59% Oper. Margin0.00% RSI (14)29.49 Volatility13.21% 9.34%
Employees9 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price32.12
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-370.95% Payout- Rel Volume0.23 Prev Close2.08
Sales Surprise- EPS Surprise38.91% Sales Q/Q- EarningsMar 22 AMC Avg Volume403.05K Price1.83
SMA20-26.22% SMA50-35.60% SMA200-88.26% Trades Volume94,005 Change-12.26%
Mar-22-24 09:52PM
04:15PM
Mar-13-24 09:00AM
Mar-12-24 09:00AM
Mar-04-24 09:00AM
09:00AM Loading…
Feb-13-24 09:00AM
Feb-05-24 04:41PM
Feb-01-24 08:27AM
06:00AM
Jan-30-24 09:00AM
Jan-29-24 08:26AM
Jan-23-24 09:00AM
Nov-13-23 04:05PM
Oct-12-23 09:00AM
Oct-04-23 09:00AM
09:00AM Loading…
Oct-02-23 09:00AM
Aug-14-23 07:36AM
Aug-11-23 04:10PM
Jun-29-23 09:00AM
Jun-22-23 10:24AM
Jun-12-23 04:15PM
May-22-23 09:00AM
Mar-30-23 05:42PM
Mar-13-23 09:00AM
Mar-06-23 09:00AM
Feb-13-23 04:20PM
Feb-09-23 09:42AM
Feb-07-23 09:00AM
Jan-31-23 12:00PM
Jan-10-23 09:00AM
09:00AM Loading…
Nov-18-22 09:00AM
Nov-10-22 04:30PM
Oct-25-22 11:13AM
Oct-06-22 07:00AM
Aug-15-22 05:30PM
Jul-29-22 11:45AM
Jul-26-22 08:15AM
Jul-22-22 06:30PM
Jul-14-22 09:00AM
Jun-13-22 09:00AM
May-23-22 09:00AM
May-16-22 04:01PM
Apr-06-22 09:00AM
Mar-30-22 09:00AM
Mar-24-22 09:00AM
Mar-22-22 09:00AM
Mar-15-22 09:00AM
Mar-08-22 09:00AM
Feb-07-22 09:00AM
Jan-24-22 08:00AM
Jan-20-22 09:00AM
Jan-18-22 09:00AM
Jan-13-22 01:54PM
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TIDMARSH GEORGE FDirectorDec 08 '23Sale0.5227,77114,4380Dec 12 04:48 PM
TIDMARSH GEORGE FDirectorOct 16 '23Sale0.6610,9577,24342,096Oct 17 04:12 PM
TIDMARSH GEORGE FDirectorOct 16 '23Sale0.651,8451,19927,771Oct 18 05:15 PM
TIDMARSH GEORGE FDirectorSep 28 '23Sale0.691,42998642,096Oct 02 04:09 PM
TIDMARSH GEORGE FDirectorSep 18 '23Sale0.744,0002,96039,348Sep 18 05:18 PM
TIDMARSH GEORGE FDirectorSep 15 '23Sale0.739,5006,93543,348Sep 18 05:18 PM
TIDMARSH GEORGE FDirectorSep 14 '23Sale0.7512,0009,00052,848Sep 18 05:18 PM
TIDMARSH GEORGE FDirectorApr 18 '23Buy1.1625,00029,00064,848Apr 19 06:00 PM
TIDMARSH GEORGE FDirectorApr 17 '23Buy1.1626,50030,74039,848Apr 19 06:00 PM